source: Boston Scientific Corporation

Boston Scientific Announces Launch
of New Balloon Catheters


NATICK, Mass., Dec. 2 -- Boston Scientific Corporation announced today the launch of two new balloon catheters in the United States, the Maverick2™ Monorail™ Coronary Balloon Dilatation Catheter and the Quantum™ Maverick® Coronary Balloon Dilatation Catheter. Both have been approved by the U.S. Food and Drug Administration and have already been launched in international markets.

"The addition of these two products further strengthens Boston Scientific's leadership in balloon catheter technology worldwide," said Paul LaViolette, Boston Scientific Senior Vice President and Group President, Cardiovascular. "They are well-suited for challenging situations and will provide clinicians options for a wide range of applications."

Maverick2 Monorail Coronary Balloon Dilatation Catheter
The Maverick2 balloon catheter incorporates a full-length hypotube that provides enhanced pushability, excellent shaft balance and outstanding shaft durability. In addition, the lower profile shaft is designed for procedural versatility.

"The Maverick2 Monorail balloon catheter is a great treatment option for challenging clinical cases," said Antonio Colombo, M.D. EMO Centro Cuore Columbus, Milan. "The catheter's lower profile shaft, pushability and durability is designed to allow physicians to treat lesions of great complexity."

The Maverick2 balloon catheter features the TrakTip™, which is attached via laser bonding to create a flexible, kink-resistant taper. The TrakTip's small lesion entry profile is also designed to enable excellent crossability and easy lesion engagement.

Quantum Maverick Coronary Balloon Dilatation Catheter
The Quantum Maverick product is an adjunctive balloon catheter that utilizes performance enhanced Quantum™ LEAP® balloon material. The combination of proprietary Maverick catheter technology with enhanced Quantum LEAP balloon material (featuring Hinge™ Balloon Technology) is designed to provide physicians with more deliverable dilatation force.

"We are finding in our lab that the Quantum Maverick balloon catheter delivers the necessary dilatation force to properly post-dilate a stent or resistant lesion," said Peter Ver Lee, M.D., Director, Cardiac Catheterization Lab, Eastern Maine Medical Center in Bangor. "It delivered beautifully in tortuous and difficult-to-reach anatomy."

The Quantum Maverick balloon catheter is available in both Monorail® and Over-The-Wire versions and replaces the Company's Quantum™ Ranger™ and Quantum™ Monorail™ balloon catheters.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with the regulatory approval process, commercialization of new technologies, competitive offerings, intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.


Contacts  
Milan Kofol (508-650-8569)
Investor Relations
Boston Scientific Corporation

Paul Donovan (508-650-8541)
Media Relations
Boston Scientific Corporation